Update on Combination Basal Insulin Plus GLP-1 Receptor Agonist: how far have we gone ? — ASN Events
  1. Schedule
  2. ADS Plenary Lectures
  3. Update on Combination Basal Insulin Plus GLP-1 Receptor Agonist: how far have we gone ?

Update on Combination Basal Insulin Plus GLP-1 Receptor Agonist: how far have we gone ? (#63)

Julio Rosenstock 1
  1. Dallas Diabetes and Endocrine Center at Medical City and University of Texas Southwestern Medical Center, Dallas, Texas, USA
Publish consent withheld
  1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetes Care 2012; 35:1364-79
  2. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes, Diabetologia 2015; 58:429-42.
  3. Scholz GH and Fleischmann H. Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making, Ther Adv Endocrinol Metab 2014; 5:95-123.
  4. Sheffield CA, Kane MP, Busch RS, Bakst G, et al. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus, Endocr Pract 2008; 14:285-92.
  5. Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, et al. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin, Endocr Pract 2007; 13:444-50.
  6. Yoon NM, Cavaghan MK, Brunelle RL and Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting, Clin Ther 2009; 31:1511-23.
  7. John L. Expanded use of exenatide in the management of type 2 diabetes, Diabetes Spectrum 2007; 20:59-63.
  8. Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ, Rosenstock J. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial, Ann Intern Med 2011; 154:103-12.
  9. Diamant M, Nauck MA, Shaginian R, Malone JK, et al. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes, Diabetes Care 2014; 37:2763-73
  10. Rosenstock J, Fonseca VA, Gross JL, Ratner RE, et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro, Diabetes Care 2014; 37:2317-25.
  11. Devries JH, Bain SC, Rodbard HW, Seufert J, D'Alessio D, Thomsen AB, Zychma M, Rosenstock J. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets, Diabetes Care 2012; 35:1446-54.
  12. Rosenstock J, Rodbard HW, Bain SC, D'Alessio D, et al. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target, J Diabetes Complications 2013; 27:492-500
  13. Riddle MC, Forst T, Aronson R, Sauque-Reyna L, Souhami E, Silvestre L, Ping L, Rosenstock J. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine: A 24-Week, Randomized, Placebo-Controlled Study (GETGOAL-DUO-1). Diabetes Care 2013; 36(9):2497-50
  14. Rosenstock K, Hanefeld M, Gentile S, Aronson R, Tinahones FJ, Guerci B, Roy-Duval C, Souhami E, Wardecki M, Ye J, Heller S. Advancing Basal Insulin Glargine with Prandial Lixisenatide QD vs Insulin Glulisine QD or TID in T2DM: The GetGoal-Duo2 Evidence-Based Trial Diabetes 2015;64 (suppl 1A):Abstract 107-LB
  15. Gough SC, Bode B, Woo V, Rodbard HW, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes, Lancet Diabetes Endocrinol 2014; 2:885-93.
  16. Buse JB, Vilsboll T, Thurman J, Blevins TC, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira), Diabetes Care 2014; 37:2926-33.
  17. Rosenstock J, Diamant M, Silvestre L, Souhami E, Tianyuezhou, Fonseca V. Benefits of a fixed-ratio formulation of once-daily insulin glargine/lixisenatide (LixiLan) vs glargine in type 2 diabetes inadequately controlled on metformin, Diabetologia 2014; 51 (Suppl. 1):Abstract 241